Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for Cognitive Impairment Associated with Schizophrenia

Alto Neuroscience received FDA Fast Track designation for ALTO-101 for treating cognitive impairment associated with schizophrenia (CIAS). ALTO-101, a...